Your Prostate Cancer Questions Answered

Prostate Cancer and Making Sense of nmCRPC Treatment Options

What Treatment Options Are Available for Non-Metastatic Castration-Resistant Prostate Cancer?

In 2018, patients with non-metastatic castration-resistant prostate cancer (nmCRPC) were watching and waiting. Two years later, there are three novel androgen receptor inhibitors available for the treatment of nmCRPC. But with these new options available, patients and doctors have questions on which treatment is right for them and what to do next.

In this first installment of our prostate cancer Answers Now series, prostate cancer experts discuss these emerging questions around who should use what – plus when, and why! They also give an overview of the disease and the new treatment options. Watch as AnCan Founder Rick Davis and AnCan Prostate Cancer Moderator Len Sierra guide this discussion along with Dr. Tom Beer, Chair of Prostate Cancer Research at OSHU in Oregon, and Dr. Eleni Efstathiou from MD Anderson Cancer Center in Maryland. They are also joined by Patient Power co-founder Andrew Schorr.

This is Part 1 of a 3-Part series. Part 2 and 3 coming soon.

This program is sponsored by Bayer. This organization has no editorial control. It is produced by Patient Power, and Patient Power is solely responsible for program content.

This article was originally published December 9, 2020 and most recently updated November 11, 2021.
© 2024 HealthCentral LLC. All rights reserved.